📣 Check out this report of chemo refractory metastatic penile SCC with extreme durable response to pembrolizumab by jc et al. Read #OpenAccess 👉 fro.ntiers.in/nccH Philippe spiess Rohit Jain, MD Moffitt Cancer Center Moffitt Research #PenileCancer #UroOnc #ImmunoOnc

Sumanta K. Pal, MD, FASCO Nazli Dizman Luis A. Meza Paulo G Bergerot @TGen City of Hope Sumanta K. Pal, MD, FASCO What an inspiring thread for all young investigators !! Thanks so much for the decades of experience and wisdom distilled through this thread Kira MacDougall, M.D. Neeraj Agarwal, MD, FASCO Rohit Jain, MD Shuchi Gulati MD

Dr Mehta giving updates in gastroesophageal cancer at the 1st annual Highlights in GI Oncology. @drjasonstarr Hani M Babiker MD Eileen M O’Reilly Rutika Mehta Mitesh Borad, M.D. Mayo Clinic Comprehensive Cancer Center Aparna Raj Parikh Tanios Bekaii-Saab, MD Moffitt Cancer Center

WATCH: Rutika Mehta, MD, MPH, discusses which pts w/ ESCC may benefit most from the different frontline treatment options available and highlights key treatment developments with adjuvant immunotherapy plus chemotherapy. #oncology #medtwitter ow.ly/JAyU50MQj0M

Monoclonal antibodies (non-ICI) for metastatic #urothelialcarcinoma #bladdercancer-we review previously investigated targets (VEGF,VEGFR2,Her2,Her3, FGFR3,KIR2) & those undergoing investigation (IL6,CD38,CD40,BTLA,RNP)-need #precisiononcology Rohit Jain, MD tandfonline.com/doi/full/10.10…

Read our mini-article on what a urologist needs to know in the management of ICU related AEs in NMIBC. Critical for urologists to develop comfort recognizing and managing these as immunotherapy is introduced earlier in BCa. Roger Li Rohit Jain, MD protect-us.mimecast.com/s/QAEICmZ7lxhV…

When Jeffrey Ehas was diagnosed with cancer, he and his wife, Lauren Ehas, turned to Moffitt Cancer Center in Tampa, Florida for treatment. #blcsm | Rohit Jain, MD Moffitt Cancer Center cancernetwork.com/view/don-t-be-…

Just in Nature Medicine👉Results from Ph3 TALAPRO-2 trial in 399 pts w/ HRR-deficient mCRPC #prostatecancer👉enza + tala vs. enza, rPFS HR 0.44, OS trending strongly HR 0.69, efficacy in multiple HRR gene subsets⬇️open access👉tinyurl.com/wntrx75a OncoAlert PCF Science

#GU24 #bladdercancer #urothelialcarcinoma preview: PemCab Phse II #clinicaltrial- Cabozantinib + pembrolizumab as first-line therapy for cisplatin-ineligible advanced urothelial carcinoma- oral presentation by Rohit Jain, MD Moffitt Cancer Center- Is there a role for VEGF inhibitors in this

Phase Ib trial of erdafitinib combined with enfortumab vedotin following platinum and PD-1/L1 inhibitors for metastatic #UrothelialCarcinoma with FGFR2/3 genetic alterations. Presented by Rohit Jain, MD Moffitt Cancer Center. #GU24 written coverage by Zach Klaassen > bit.ly/49aVllN

#GU24 #bladdercancer highlights in my opinion: 1) AMBASSADOR Phase III Andrea Apolo, M.D.-improved DFS for adjuvant pembro x 1 year vs. observation in high-risk muscle-invasive #urothelialcarcinoma (HR 0.69, median 29 v 14 mo, OS immature), 2) EV302 Phase III Michiel van der Heijden: improved

Pembrolizumab plus cabozantinib was efficacious in the first-line treatment of patients with cisplatin-ineligible urothelial carcinoma. Rohit Jain, MD Moffitt Cancer Center ASCO #GU24 #blcsm onclive.com/view/frontline…

First-line pembrolizumab plus cabozantinib was efficacious and had a manageable toxicity profile in patients with advanced urothelial carcinoma, including those who were ineligible for cisplatin. Rohit Jain, MD Moffitt Cancer Center ASCO #GU24 #blcsm onclive.com/view/frontline…

A study from Rohit Jain, MD and colleagues presented at #GU24 showed that #cabozantinib plus #pembrolizumab exhibited a manageable toxicity profile and promising efficacy in treating patients with cisplatin-ineligible #mUC. Learn more: buff.ly/488Qxg2

Rohit K. Jain, MD, MPH, on Urothelial Carcinoma: New Data on Cabozantinib Plus Pembrolizumab ascopost.com/videos/2024-as… #blcsm #bladdercancer #immunotherapy #oncology #GU24 Rohit Jain, MD Moffitt Cancer Center

May is #BladderCancerAwarenessMonth 📣 And we are passionate about bringing you the latest news and updates 🎥 🗞️ Rohit Jain, MD talks to us about sequencing ADCs and finding novel #biomarkers for #urothelialcarcinoma 👉 ow.ly/wKI750RsjrA

Circulating tumor DNA molecular analyses and real-world evidence outcomes of FGFR2 amplified gastroesophageal cancers academic.oup.com/oncolo/article… Steve Maron Sam Klempner @genesdontfit Leylah Drusbosky Guardant Health #GEAs #ctDNA

Dr. Rohit Jain (Rohit Jain, MD) was first author on #research from ASCO #GU25 evaluating erafitinib + enfortumab vedotin for a subset of metastatic #BladderCancer patients following treatment with #chemotherapy and/or PD-1/L1 inhibitors (Abstract 808 bit.ly/3QpXvXf)

Join us in our social media welcome for #GI medical oncologist Dr. Rutika Mehta (Rutika Mehta)! Dr. Mehta is available for appointments for patients with all types of #GastrointestinalCancer: bit.ly/42WsKkm

A wonderful group here at #AtlantaGU25🦸! Rohit Jain, MD of Weill Cornell Medicine , Arnab Basu from UAB O'Neal Comprehensive Cancer Center , and Dr. Jacqueline Brown from Winship Cancer Institute of Emory University team together to educate us on #bladdercancer. Session Chair: Dr. Shreyas Joshi of Winship Cancer Institute of Emory University . 🌟Visit